Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 30, 2024

SELL
$1.27 - $3.18 $2,025 - $5,072
-1,595 Reduced 76.98%
477 $1,000
Q3 2023

Oct 25, 2023

SELL
$1.7 - $3.07 $561 - $1,013
-330 Reduced 13.74%
2,072 $3,000
Q2 2023

Aug 07, 2023

SELL
$2.83 - $3.87 $1,932 - $2,643
-683 Reduced 22.14%
2,402 $7,000
Q1 2023

May 08, 2023

BUY
$2.3 - $8.25 $7,095 - $25,451
3,085 New
3,085 $8,000
Q2 2022

Aug 09, 2022

SELL
$2.13 - $5.38 $5,693 - $14,380
-2,673 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $78,693 - $116,917
2,673 New
2,673 $79,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $16.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.